Improving Care After Inherited Cancer Testing (IMPACT) Study (IMPACT)

  • STATUS
    Recruiting
  • End date
    Dec 22, 2028
  • participants needed
    720
  • sponsor
    Vanderbilt-Ingram Cancer Center
Updated on 22 October 2022
cancer
Accepts healthy volunteers

Summary

The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genetic test results. These interventions will be delivered to individuals with a documented pathogenic/likely pathogenic (P/LP) variant or variant of uncertain significance (VUS) in an inherited cancer gene.

Description

Through recruitment of a racially, geographically, and socioeconomically diverse sample of patients, we will achieve the following aims:

  1. Evaluate factors associated with access to genetic risk assessment, counseling, and testing services
  2. Conduct a randomized controlled trial to assess the effectiveness of interventions on improving guideline-adherent CRM and FC of genetic test results
  3. Create and pilot an adaptive intervention to tailor resources to promote CRM and FC
  4. Document and compare multiple implementation outcomes across the different interventions to maximize their effectiveness and improve reach to underserved populations

Details
Condition Inherited Cancer Syndrome, Prostate Cancer, Colorectal Cancer, Endometrial Cancer, Breast Cancer
Treatment Correlative Studies (Survey), Correlative Studies (Interview), GeneSHARE, LivingLabReport, Standard-of-care & Adaptive Intervention
Clinical Study IdentifierNCT04763915
SponsorVanderbilt-Ingram Cancer Center
Last Modified on22 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

English-speaking
Not adopted (i.e., have information about their biological relatives)
Have an email address with access to internet and a computer, tablet, or smartphone
Documented pathogenic/likely pathogenic variant or VUS in an inherited cancer gene that has CRM guidelines listed in the National Comprehensive Cancer Network (NCCN) Genetic/Familial Panel focused on Breast, Ovarian, and Pancreatic or Colorectal cancers
Are non-adherent (i.e., either undertreatment or overtreatment) to at least one of the current NCCN CRM guidelines or if currently adherent, require ongoing cancer screening
Have at least one at-risk adult, living relative who either
has not been told about the genetic test result (if P/LP variant result) or family history of cancer (if VUS result) by the participant
has not had their own genetic testing if the participant has a pathogenic/likely pathogenic variant
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note